Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Feb 12. pii: S1535-6108(19)30042-X. doi: 10.1016/j.ccell.2019.01.008. [Epub ahead of print]

PMID:
30773341
2.

RNA sequencing identifies a novel USP9X-USP6 promoter swap gene fusion in a primary aneurysmal bone cyst.

Blackburn PR, Davila JI, Jackson RA, Fadra N, Atiq MA, Pitel BA, Nair AA, Van De Walker TJ, Hessler MG, Hovel SK, Wehrs RN, Fritchie KJ, Jenkins RB, Halling KC, Geiersbach KB.

Genes Chromosomes Cancer. 2019 Feb 14. doi: 10.1002/gcc.22742. [Epub ahead of print]

PMID:
30767316
3.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

PMID:
30761387
4.

Transcriptome-wide association study identifies new candidate susceptibility genes for glioma.

Atkins I, Kinnersley B, Ostrom QT, Labreche K, Il'yasova D, Armstrong GN, Eckel-Passow JE, Schoemaker MJ, Nöthen MM, Barnholtz-Sloan JS, Swerdlow AJ, Simon M, Rajaraman P, Chanock SJ, Shildkraut J, Bernstein JL, Hoffmann P, Jöckel KH, Lai RK, Claus EB, Olson SH, Johansen C, Wrensch MR, Melin B, Jenkins RB, Sanson M, Bondy ML, Houlston RS.

Cancer Res. 2019 Feb 1. pii: canres.2888.2018. doi: 10.1158/0008-5472.CAN-18-2888. [Epub ahead of print]

PMID:
30709929
5.

Sleeping Beauty insertional mutagenesis reveals important genetic drivers of central nervous system embryonal tumors.

Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, Picard D, Wu X, Rodriguez FJ, Rosemarie Q, Krebs RD, Molan AM, Demer AM, Frees MM, Rizzardi AE, Schmechel SC, Eberhart CG, Jenkins RB, Wechsler-Reya RJ, Odde DJ, Huang A, Taylor MD, Sarver AL, Largaespada DA.

Cancer Res. 2019 Jan 23. pii: canres.1261.2018. doi: 10.1158/0008-5472.CAN-18-1261. [Epub ahead of print]

PMID:
30674530
6.

Using germline variants to estimate glioma and subtype risks.

Eckel-Passow JE, Decker PA, Kosel ML, Kollmeyer TM, Molinaro AM, Rice T, Caron A, Drucker KL, Praska C, Pekmezci M, Hansen HM, McCoy LS, Bracci PM, Erickson BJ, Lucchinetti C, Wiemels J, Wiencke JK, Bondy ML, Melin B, Burns TC, Giannini C, Lachance DH, Wrensch M, Jenkins RB.

Neuro Oncol. 2019 Jan 8. doi: 10.1093/neuonc/noz009. [Epub ahead of print]

PMID:
30624711
7.

Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.

Jin Z, Holubek M, Sukov WR, Sattler CA, Wiktor AE, Jenkins RB, Wu TT, Yoon HH.

Am J Clin Oncol. 2019 Feb;42(2):190-195. doi: 10.1097/COC.0000000000000495.

PMID:
30516569
8.

Aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis.

Amirian ES, Ostrom QT, Armstrong GN, Lai RK, Gu X, Jacobs DI, Jalali A, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut JM, Ali-Osman F, Sadetzki S, Jenkins RB, LaChance DH, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Johansen C, Houlston RS, Scheurer ME, Shete S, Amos CI, Melin B, Bondy ML.

Cancer Epidemiol Biomarkers Prev. 2018 Nov 27. pii: cebp.0702.2018. doi: 10.1158/1055-9965.EPI-18-0702. [Epub ahead of print]

PMID:
30482874
9.

Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy.

Blessing MM, Blackburn PR, Balcom JR, Krishnan C, Harrod VL, Zimmermann MT, Barr Fritcher EG, Zysk CD, Jackson RA, Nair AA, Jenkins RB, Halling KC, Kipp BR, Ida CM.

Acta Neuropathol Commun. 2018 Nov 5;6(1):118. doi: 10.1186/s40478-018-0622-1. No abstract available.

10.

Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain.

Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, Ramakrishnan S, Poduslo JF, Kandimalla KK.

Nanomedicine. 2018 Oct 6. pii: S1549-9634(18)30529-X. doi: 10.1016/j.nano.2018.09.010. [Epub ahead of print]

PMID:
30300748
11.

Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.

Aypar U, Smoley SA, Pitel BA, Pearce KE, Zenka RM, Vasmatzis G, Johnson SH, Smadbeck JB, Peterson JF, Geiersbach KB, Van Dyke DL, Thorland EC, Jenkins RB, Ketterling RP, Greipp PT, Kearney HM, Hoppman NL, Baughn LB.

Eur J Haematol. 2019 Jan;102(1):87-96. doi: 10.1111/ejh.13179. Epub 2018 Nov 22.

PMID:
30270457
12.

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M.

Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26. No abstract available.

PMID:
30259105
13.

Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age.

Ostrom QT, Kinnersley B, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Eckel-Passow JE, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Rubin JB, Andersson U, Rajaraman P, Chanock SJ, Linet MS, Wang Z, Yeager M; GliomaScan consortium, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Bondy ML, Barnholtz-Sloan JS.

Int J Cancer. 2018 Nov 15;143(10):2359-2366. doi: 10.1002/ijc.31759. Epub 2018 Sep 19.

PMID:
30152087
14.

Sex-specific gene and pathway modeling of inherited glioma risk.

Ostrom QT, Coleman W, Huang W, Rubin JB, Lathia JD, Berens ME, Speyer G, Liao P, Wrensch MR, Eckel-Passow JE, Armstrong G, Rice T, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Houlston RS, Il'yasova D, Jenkins RB, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Andersson U, Rajaraman P, Chanock SJ, Linet MS, Wang Z, Yeager M; GliomaScan consortium , Melin B, Bondy ML, Barnholtz-Sloan JS.

Neuro Oncol. 2019 Jan 1;21(1):71-82. doi: 10.1093/neuonc/noy135.

PMID:
30124908
15.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

PMID:
30108099
16.

Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors.

Winters JL, Davila JI, McDonald AM, Nair AA, Fadra N, Wehrs RN, Thomas BC, Balcom JR, Jin L, Wu X, Voss JS, Klee EW, Oliver GR, Graham RP, Neff JL, Rumilla KM, Aypar U, Kipp BR, Jenkins RB, Jen J, Halling KC.

J Mol Diagn. 2018 Jul;20(4):495-511. doi: 10.1016/j.jmoldx.2018.03.007. Epub 2018 Jun 19.

17.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.

PMID:
29846122
18.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30.

PMID:
29846104
19.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. doi: 10.1158/1078-0432.CCR-17-2745. Epub 2018 May 14.

PMID:
29760221
20.

Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.

Ostrom QT, Kinnersley B, Wrensch MR, Eckel-Passow JE, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Rubin JB, Lathia JD, Berens ME, Andersson U, Rajaraman P, Chanock SJ, Linet MS, Wang Z, Yeager M; GliomaScan consortium, Houlston RS, Jenkins RB, Melin B, Bondy ML, Barnholtz-Sloan JS.

Sci Rep. 2018 May 9;8(1):7352. doi: 10.1038/s41598-018-24580-z.

21.

Copy number variant analysis using genome-wide mate-pair sequencing.

Smadbeck JB, Johnson SH, Smoley SA, Gaitatzes A, Drucker TM, Zenka RM, Kosari F, Murphy SJ, Hoppman N, Aypar U, Sukov WR, Jenkins RB, Kearney HM, Feldman AL, Vasmatzis G.

Genes Chromosomes Cancer. 2018 Sep;57(9):459-470. doi: 10.1002/gcc.5. Epub 2018 Jul 30.

PMID:
29726617
22.

Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study.

Berntsson SG, Merrell RT, Amirian ES, Armstrong GN, Lachance D, Smits A, Zhou R, Jacobs DI, Wrensch MR, Olson SH, Il'yasova D, Claus EB, Barnholtz-Sloan JS, Schildkraut J, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Bernstein JL, Lai R, Shete S, Amos CI, Bondy ML, Melin BS.

J Neurol. 2018 Jun;265(6):1432-1442. doi: 10.1007/s00415-018-8857-0. Epub 2018 Apr 23.

23.

Impact of atopy on risk of glioma: a Mendelian randomisation study.

Disney-Hogg L, Cornish AJ, Sud A, Law PJ, Kinnersley B, Jacobs DI, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

BMC Med. 2018 Mar 15;16(1):42. doi: 10.1186/s12916-018-1027-5.

24.

Influence of obesity-related risk factors in the aetiology of glioma.

Disney-Hogg L, Sud A, Law PJ, Cornish AJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Swerdlow AJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

Br J Cancer. 2018 Apr;118(7):1020-1027. doi: 10.1038/s41416-018-0009-x. Epub 2018 Mar 13.

PMID:
29531326
25.

SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq).

Johnson SH, Smadbeck JB, Smoley SA, Gaitatzes A, Murphy SJ, Harris FR, Drucker TM, Zenka RM, Pitel BA, Rowsey RA, Hoppman NL, Aypar U, Sukov WR, Jenkins RB, Feldman AL, Kearney HM, Vasmatzis G.

Cancer Genet. 2018 Feb;221:1-18. doi: 10.1016/j.cancergen.2017.11.009. Epub 2017 Dec 2.

PMID:
29405991
26.

Mendelian randomisation study of the relationship between vitamin D and risk of glioma.

Takahashi H, Cornish AJ, Sud A, Law PJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Ll'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Turnbull C, Houlston RS.

Sci Rep. 2018 Feb 5;8(1):2339. doi: 10.1038/s41598-018-20844-w.

27.

Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series.

Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ.

Urology. 2018 Feb;112:29-32. doi: 10.1016/j.urology.2017.10.016. Epub 2017 Oct 25.

PMID:
29079212
28.

Molecular subtyping of tumors from patients with familial glioma.

Ruiz VY, Praska CE, Armstrong G, Kollmeyer TM, Yamada S, Decker PA, Kosel ML, Eckel-Passow JE, Lachance DH, Bainbridge MN, Melin BS, Bondy ML, Jenkins RB; Gliogene Consortium.

Neuro Oncol. 2018 May 18;20(6):810-817. doi: 10.1093/neuonc/nox192.

PMID:
29040662
29.

Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process.

Ida CM, Butz ML, Jenkins RB, Sarkaria JN, Kitange GJ, Giannini C, Kipp BR.

Am J Clin Pathol. 2017 Oct 1;148(4):296-307. doi: 10.1093/ajcp/aqx073.

PMID:
28967952
30.

Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile.

Takami H, Graffeo CS, Perry A, Raghunathan A, Jenkins RB, Giannini C, Burns TC.

World Neurosurg. 2017 Dec;108:997.e9-997.e14. doi: 10.1016/j.wneu.2017.09.088. Epub 2017 Sep 21. Review.

PMID:
28943417
31.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

32.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

33.

Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism.

Vaubel RA, Kollmeyer TM, Caron AA, Barr Fritcher EG, Voss JS, Liang H, Jenkins RB, Giannini C, Kipp BR.

Acta Neuropathol. 2017 Aug;134(2):317-319. doi: 10.1007/s00401-017-1727-5. Epub 2017 May 26. No abstract available.

PMID:
28550371
34.

IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.

Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA.

Clin Cancer Res. 2017 Aug 1;23(15):4203-4211. doi: 10.1158/1078-0432.CCR-15-0574. Epub 2017 May 22.

35.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.

36.

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR.

Oncotarget. 2017 Apr 18;8(16):27145-27154. doi: 10.18632/oncotarget.16057.

37.

Genetic landscape of extreme responders with anaplastic oligodendroglioma.

Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C.

Oncotarget. 2017 May 30;8(22):35523-35531. doi: 10.18632/oncotarget.16773.

38.

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussière M, Idbaih A, Hoang-Xuan K, Di Stefano AL, Mokhtari K, Delattre JY, Broderick P, Galan P, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Nöthen MM, Wichmann HE, Schreiber S, Swerdlow A, Lathrop M, Simon M, Sanson M, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M; GliomaScan Consortium, Wiencke JK, Hansen H, McCoy L, Rice T, Kosel ML, Sicotte H, Amos CI, Bernstein JL, Davis F, Lachance D, Lau C, Merrell RT, Shildkraut J, Ali-Osman F, Sadetzki S, Scheurer M, Shete S, Lai RK, Claus EB, Olson SH, Jenkins RB, Houlston RS, Bondy ML.

Nat Genet. 2017 May;49(5):789-794. doi: 10.1038/ng.3823. Epub 2017 Mar 27.

39.

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR.

Acta Neuropathol. 2017 Jun;133(6):1001-1016. doi: 10.1007/s00401-017-1690-1. Epub 2017 Mar 2.

40.

Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.

Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R.

Oncotarget. 2017 Mar 21;8(12):18949-18967. doi: 10.18632/oncotarget.14850.

41.

Localized Temperature Variations in Laser-Irradiated Composites with Embedded Fiber Bragg Grating Sensors.

Jenkins RB, Joyce P, Mechtel D.

Sensors (Basel). 2017 Jan 27;17(2). pii: E251. doi: 10.3390/s17020251.

42.

Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.

Johnson DR, Diehn FE, Giannini C, Jenkins RB, Jenkins SM, Parney IF, Kaufmann TJ.

AJNR Am J Neuroradiol. 2017 Apr;38(4):678-684. doi: 10.3174/ajnr.A5070. Epub 2017 Jan 26.

43.

Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.

Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jiménez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS.

BJU Int. 2017 Jun;119(6):961-967. doi: 10.1111/bju.13779. Epub 2017 Feb 11.

44.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.

45.

Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.

Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN.

Clin Genitourin Cancer. 2017 Jun;15(3):e299-e309. doi: 10.1016/j.clgc.2016.08.012. Epub 2016 Aug 17.

PMID:
28089723
46.

MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.

Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA.

Cancer Res. 2017 Feb 15;77(4):1021-1034. doi: 10.1158/0008-5472.CAN-16-2529. Epub 2016 Dec 23.

47.

Impact of RNA degradation on fusion detection by RNA-seq.

Davila JI, Fadra NM, Wang X, McDonald AM, Nair AA, Crusan BR, Wu X, Blommel JH, Jen J, Rumilla KM, Jenkins RB, Aypar U, Klee EW, Kipp BR, Halling KC.

BMC Genomics. 2016 Oct 20;17(1):814.

48.

Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential.

Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE.

J Urol. 2017 Jan;197(1):122-128. doi: 10.1016/j.juro.2016.08.091. Epub 2016 Aug 26.

PMID:
27569435
49.

Assessing the Cost of Global Biodiversity and Conservation Knowledge.

Juffe-Bignoli D, Brooks TM, Butchart SH, Jenkins RB, Boe K, Hoffmann M, Angulo A, Bachman S, Böhm M, Brummitt N, Carpenter KE, Comer PJ, Cox N, Cuttelod A, Darwall WR, Di Marco M, Fishpool LD, Goettsch B, Heath M, Hilton-Taylor C, Hutton J, Johnson T, Joolia A, Keith DA, Langhammer PF, Luedtke J, Nic Lughadha E, Lutz M, May I, Miller RM, Oliveira-Miranda MA, Parr M, Pollock CM, Ralph G, Rodríguez JP, Rondinini C, Smart J, Stuart S, Symes A, Tordoff AW, Woodley S, Young B, Kingston N.

PLoS One. 2016 Aug 16;11(8):e0160640. doi: 10.1371/journal.pone.0160640. eCollection 2016.

50.

Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.

Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins RB, Sicotte H, Kollmeyer TM, O'Neill BP, Elmquist W, Hoxworth JM, Frakes D, Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR.

Neuro Oncol. 2017 Jan;19(1):128-137. doi: 10.1093/neuonc/now135. Epub 2016 Aug 8.

Supplemental Content

Loading ...
Support Center